• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Packaging Technology

    Elemental Impurities: The Time Has Come

    Continuous vs. Batch Production

    2018: The evolution of pharmaceutical packaging

    Formulation Development Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Thermo Fisher Invests $50M to Grow Biologics Footprint

    Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

    Synpromics, Lonza Enter Partnership

    Noramco, SPI Pharma Sign Agreement

    Codexis, Porton Enter Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Thermo Fisher Invests $50M to Grow Biologics Footprint

    Codexis, Porton Enter Collaboration

    WuXi AppTec Opens Laboratory Testing Facility in NJ

    Arcinova Receives £1.5M Innovate UK Grant

    Vetter Welcomes Illinois Governor
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    Almac Group Expands Packaging Capabilities

    Catalent Bolsters Clinical Supply Capabilities

    West, Stevanato Group Enter Ompi EZ-fill Alliance

    Pharmaceutical Packaging Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

    Noramco, SPI Pharma Sign Agreement

    Codexis, Porton Enter Collaboration

    AMRI Expands NMR Spec Capabilities in Europe

    WuXi AppTec Opens Laboratory Testing Facility in NJ
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Blockchain: The Next Big Trend in BioPharma?

    Emergent Completes Market Authorization

    Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12

    LSNE Expands Capabilities and QC Laboratory Space

    Evotec Launches Drug Development Service
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    SeránCascade

    iuvo BioScience

    Avid Bioservices, Inc.

    Exelead
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Nutritional Supplement Update

    What’s going on with nutraceuticals and medical foods?

    Related CONTENT
    • Biogen’s SPINRAZA Wins FDA Approval
    • Navigating the Shifting Landscape of Contract API Manufacturing
    • NEMUS, Catalent to Advance NB1222 for Clinical Trials
    • Contract Manufacturing in the Supplement Industry
    • Formulation Strategies for Aging Consumers
    Ben Locwin, Contributing Editor03.07.17
    At the last medical conference I gave a speech at, I asked an informal poll of the audience: “How many of you, with a show of hands, takes a vitamin/mineral or other supplement?” The results were surprising. Well over 90% of the audience raised their hands, simultaneous with a wry smile as though they were catching themselves doing something that they would advise against.

    The supplement industry in the U.S. is estimated at $35 billion last year, according to Statista, and is expected to reach $278 billion worldwide by 2024 based on data from Grand View Research, Inc. This worldwide growth also includes the medical foods market. Recently, Nestlé announced groundbreaking strategies to approach fortified medical foods—a market estimated at $15 billion—banking on the segment to the tune of $500 million, which is the budget to 2021 at Nestlé’s Institute of Health Science (NIHS) in Lausanne, Switzerland.

    The nutraceutical and medical foods industries are in an interesting place at the moment. Dietary supplements represent a market that has defied all analysts’ expectations and has grown even when competitor markets have shrunk. The interesting thing about these markets is that they represent a forward-looking advancement philosophy to the foods and nutrients we eat (‘improving on nature’), which is in stark contrast to the majority of popular media about foods—the messages which espouse whole foods, unprocessed foods, raw foods, and organic or non-GMO foods. So the public has a bit of an identity crisis within itself. Do people want raw, organic, unprocessed foods in all practical cases? Or do we want to put our faith in nutraceutical supplements to give us high-dose specific micronutrients that we may be lacking?

    The real science
    Of course, I’ll give you the real science, which suggests in-aggregate that nutraceuticals aren’t very effective for people. For example, curcumin, which has been touted for everything from treatment for Alzheimer’s disease to bone loss to baldness has recently shown to be less-effective than previously thought. Perhaps it’s due to assay confounding. The authors of this research on curcumin chemistry noted, “Curcumin has recently been classified as both a PAINS (pan-assay interference compounds) and an IMPS (invalid metabolic panaceas) candidate. The likely false activity of curcumin in vitro and in vivo has resulted in >120 clinical trials of curcuminoids against several diseases. No double-blinded, placebo controlled clinical trial of curcumin has been successful.”3

    Let’s look at the multivitamin/mineral market. It is estimated to be worth about $12 billion annually, and about 53% of American adults (>70% of those 65 and older) take these supplements. Similarly, Larry Appel, director of the Johns Hopkins Welch Center for Prevention, Epidemiology, and Clinical Research noted that, “Pills are not a shortcut to better health and the prevention of chronic diseases.” Appel was co-author of an article2 in the Annals of Internal Medicine (2013), which looked at various studies of vitamin/mineral supplements. Here’s some of what the researchers found:
    • An analysis of several research papers involving 450,000 people found that multivitamins did not reduce risk for heart disease or cancer;
    • A study that tracked the multivitamin use of 5,947 men for 12 years found that multivitamins/minerals did not improve overall cognitive performance or verbal memory; and
    • A study of 1,708 heart attack survivors who took a high-dose multivitamin or placebo were followed for up to 55 months. Rates of later heart attacks, heart surgeries and deaths were similar in the two groups. The authors noted, “After a median follow-up of 4.6 years, there was no significant difference in recurrent cardiovascular events with multivitamins compared with placebo—hazard ratio, 0.89 (95% CI, 0.75 to 1.07).”
    They also reported that, “Evidence involving tens of thousands of people randomly assigned in many clinical trials shows that β-carotene, vitamin E, and possibly high doses of vitamin A supplements increase mortality, and that other antioxidants, folic acid and B vitamins, and multivitamin supplements have no clear benefit.” It should be noted that the exception is folic acid for women of child bearing potential, where it has been shown to prevent neural tube defects in babies when women take it before and during early pregnancy. Ergo, Guallar and his colleagues showed that there was no specific reason to take multivitamins, and that they didn’t confer any health benefits to those who took them. In fact, researchers found certain cancers more often in people who were taking vitamins, though I’ll leave that as a simple correlation and not draw any causality links to it here.

    Counterpoint
    However, most nutritional supplements, nutraceuticals, and medical foods are measured by a very crude yardstick. There often aren’t mechanistic biological studies of nutraceuticals and what they’re doing at a cellular and molecular level to elicit biological and physiological effects, but instead they are measured by extraordinarily low resolution clinical measures such as, “did _____(symptom) resolve?” Unfortunately, like any other clinical measure, there are innumerable factors in whether a patient’s headache or rash or other issue has abated, and these ‘other’ factors can, and often do, totally overwhelm the ability to detect effects from the supplements. It could have been their sleep status the night before the clinical appointment, whether or not they had breakfast or lunch, personal stress, etc.

    We know that many real effective drugs on the market are derived from natural plant sources. There’s no equivocation that molecules within plants and foods do have medical effects. But that’s also a long way from saying, “All foods have compounds with nutraceutical properties.” Said in another way, just because some powerful drugs, such as aspirin and digoxin, are derived from plants doesn’t mean that there are miraculous and effective compounds in all plant sources. To look for medically active compounds, it requires a bit of smarts, and empirical study above all else.

    As far as the clinical data referenced, remember, while we get strong directional evidence from large clinical trials and well conducted scientific studies, they don’t tell us what a specific individual will experience from a particular intervention. For certain nutrient deficiencies, which are very real, and in particular individuals, there can be unequivocally real effects from nutraceutical and medical food supplementation. As even Guallar and his co-authors from the Annals of Internal Medicine article observe, “Available evidence does not rule out small benefits or harms or large benefits or harms in a small subgroup of the population [from vitamin and mineral supplements].” After all, this team is the first to admit, “Clinical trials are not well-suited to identify very small effects.” This is especially the case in multiple smaller studies meta-analytically reviewed together. In fact, John Michael Gaziano, a researcher at Brigham and Women’s Hospital and the VA Boston Healthcare System and co-author of one of the studies referenced by the Annals piece said frustratingly, “It drives me crazy that they [Guallar and colleagues] say ‘enough is enough,’ [about studying vitamins and minerals] when there’s only been one large study of (standard) multivitamins and it’s ours.”

    Science is about reproducibility. Evidence trumps opinion and hope. And as the Nobel laureate Richard Feynman noted, “It doesn’t matter how beautiful your theory is, it doesn’t matter how smart you are. If it doesn’t agree with experiment, it’s wrong.” The more we continue to research supplements, nutraceuticals, and medical foods, the more we’ll know about their benefits. 

    References
    1. Dar W.R., Najeebullah, S., Dar, I., Sofi, P., & Changal, K.H. (2016). Moving beyond conventional heart failure treatment – Does micronutrient supplementation have a role? Journal of Nutraceuticals and Food Science, 1(1).
    2. Guallar, E., Stranges, S., Mulrow, C., Appel, L.J., Miller, E.R. (2013). Enough is enough: Stop wasting money on vitamin and mineral supplements. Annals of Internal Medicine.
    3. Nelson, K.M., Dahlin, J.L., Bisson, J., Graham, J. Pauli, G.F., & Walters, M.A. (2017). The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry.

    Ben Locwin

    Ben Locwin, PhD, MBA, MS heads a healthcare consultancy, advises on clinical practice, and frequently speaks on nutraceutical, nutritional, and food-based research. He was formerly a steering committee member for the American Association of Pharmaceutical Scientists’ (AAPS) Nutraceuticals and Natural Products focus group, and works on making connections in the best practices of health, medical care, science, behavior, and patient-centricity to improve the healthcare industry.
    Related Searches
    • cancer
    • Clinical Trial
    • it
    • in vivo
    Suggested For You
    Using Pragmatic Randomization in Real-World Studies Using Pragmatic Randomization in Real-World Studies
    Kemwell Provides Services for U.S. Trial Kemwell Provides Services for U.S. Trial
    Indian Generic Firms  Expand Biosimilar Portfolios Indian Generic Firms Expand Biosimilar Portfolios
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    Formulating Candidates  with Bioavailability Issues Formulating Candidates with Bioavailability Issues
    Tracking Health Tracking Health
    Volition Opens New R&D Facility in Belgium  Volition Opens New R&D Facility in Belgium
    Biomanufacturing Trends and Outlook 2017: Where Is It All Going? Biomanufacturing Trends and Outlook 2017: Where Is It All Going?
    FDA’s Final Guidance: Steering Studies to Support Biosimilar Approval FDA’s Final Guidance: Steering Studies to Support Biosimilar Approval
    IriSys Doubles Contract with NCI for Mfg. Clinical Trial Materials IriSys Doubles Contract with NCI for Mfg. Clinical Trial Materials
    Meiji Seika and Eisai Enter Parkinson’s Collaboration Meiji Seika and Eisai Enter Parkinson’s Collaboration
    Biosimilars Update Biosimilars Update
    SGS Expands Hospital Clinical Pharmacology Network SGS Expands Hospital Clinical Pharmacology Network
    Formulation Strategies for  Aging Consumers Formulation Strategies for Aging Consumers
    Contract Manufacturing in the Supplement Industry Contract Manufacturing in the Supplement Industry

    Related Columns

    • CMOs Growing Strong in APIs

      CMOs Growing Strong in APIs

      Major API players in India continue to invest in operations
      S Harachand, Contributing Editor 04.10.18

    • Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18

    • New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA
      Robert Marohn, ClinLogic, LLC 04.10.18


    • Some Changes in Formulation Paradigms

      Some Changes in Formulation Paradigms

      Old ways are slowly changing with the introduction of PAT and QbD
      Emil W. Ciurczak, DoraMaxx Consulting 04.10.18

    • How Does Work Get Done In Pharma? By PEOPLE!

      How Does Work Get Done In Pharma? By PEOPLE!

      A high-octane primer on talent development for better business performance
      Ben Locwin, Contributing Editor 04.10.18

    • Packaging is Neither Simple Nor Un-important

      Packaging is Neither Simple Nor Un-important

      Closing gaps on the packaging line will help avoid recalls
      Emil W. Ciurczak, DoraMaxx Consulting 03.12.18


    • Regulatory Affairs
      Drug Safety Update

      Drug Safety Update

      An uptick in adverse event reports doesn’t necessarily mean an increase in adverse events
      Ben Locwin 03.12.18

    • Regulatory Affairs
      OTC Drug Market Revenue to Exceed $178B by 2024

      OTC Drug Market Revenue to Exceed $178B by 2024

      Growth driven by massive demand for health supplements and analgesics
      Global Market Insights 03.09.18

    • Regulatory Affairs
      From OMUFA To Opioids

      From OMUFA To Opioids

      CDMOs get involved in policy
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 03.09.18


    • When Your Product is Neither a Liquid or a Solid

      When Your Product is Neither a Liquid or a Solid

      And you need to analyze/control it, in real time
      Emil W. Ciurczak, DoraMaxx Consulting 01.30.18

    • Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17

    • India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • cGMP Manufacture
      Flexible Manufacturing Strategies and Data Integrity

      Flexible Manufacturing Strategies and Data Integrity

      Making processes integral with your data handling ability
      Emil W. Ciurczak, DoraMaxx Consulting 11.07.17

    • Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17

    • Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17

    Breaking News
    • Thermo Fisher Invests $50M to Grow Biologics Footprint
    • Q Therapeutics, REPROCELL Form MAGiQ Therapeutics
    • Synpromics, Lonza Enter Partnership
    • Noramco, SPI Pharma Sign Agreement
    • Codexis, Porton Enter Collaboration
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • Pharmaceutical Packaging Technology
    • Elemental Impurities: The Time Has Come
    • Continuous vs. Batch Production
    • 2018: The evolution of pharmaceutical packaging
    • Formulation Development Trends
    • Changing Dynamics: The CDMO market in focus
    • Contract BioManufacturing in China: Creating a New Segment
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.